RNS Number : 0529V
Creo Medical Group PLC
12 August 2025
LEI: 213800H188ZDCWWXFA21
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Director/PDMR Share Dealing
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, was informed on 8 August 2025 that Richard Rees, Chief Financial Officer of the Company, passed the control of 362,408 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to three of his children who are now aged eighteen or older.
Consequently, Mr Rees's total beneficial interest in the Company has reduced by 362,408 Ordinary Shares to 2,707,555 1 Ordinary Shares, representing approximately 0.66% of the Company's issued share capital.
1 Including shares held by certain other PCAs of Mr Rees
For further information please contact:
Creo Medical Group plc
www.creomedical.com
Richard Craven, Company Secretary
Via Walbrook PR
Deutsche Numis (Nominated Adviser, Broker and Financial Adviser) Freddie Barnfield / Duncan Monteith / Sher Shah
+44 (0)20 7260 1000
Walbrook PR Ltd
Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Alice Woodings
Mob: +44 (0)7980 541 893 /+44 (0)7407 804 654
About Creo Medical
Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Richard John Rees
2
Reason for the notification
a)
Position/status
Chief Finance Officer
b)
Initial notification/Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Creo Medical Group plc
b)
LEI
213800H188ZDCWWXFA21
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of £0.001 each
Identification code
GB00BZ1BLL44
b)
Nature of the transaction
Transfer of Ordinary Shares
c)
Price(s) and volumes(s)
Price(s)
Volume(s)
Nil
167,038
d)
Aggregated information
Aggregated volume
167,038
Price
Nil
e)
Date of the transaction
8 August 2025
f)
Place of the transaction
London Stock Exchange
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Richard John Rees
2
Reason for the notification
a)
Position/status
Chief Finance Officer
b)
Initial notification/Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Creo Medical Group plc
b)
LEI
213800H188ZDCWWXFA21
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of £0.001 each
Identification code
GB00BZ1BLL44
b)
Nature of the transaction
Transfer of Ordinary Shares
c)
Price(s) and volumes(s)
Price(s)
Volume(s)
Nil
121,086
d)
Aggregated information
Aggregated volume
121,086
Price
Nil
e)
Date of the transaction
8 August 2025
f)
Place of the transaction
London Stock Exchange
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Richard John Rees
2
Reason for the notification
a)
Position/status
Chief Finance Officer
b)
Initial notification/Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Creo Medical Group plc
b)
LEI
213800H188ZDCWWXFA21
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of £0.001 each
Identification code
GB00BZ1BLL44
b)
Nature of the transaction
Transfer of Ordinary Shares
c)
Price(s) and volumes(s)
Price(s)
Volume(s)
Nil
74,284
d)
Aggregated information
Aggregated volume
74,284
Price
Nil
e)
Date of the transaction
8 August 2025
f)
Place of the transaction
London Stock Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHELLFFEVLEBBZ
